New heart valve device shows promise for High-Risk patients

NCT ID NCT03613246

Ongoing Disease control Sponsor: NVT GmbH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well the ALLEGRA TAVI system works in real-world patients with severe aortic valve disease who are at high risk for surgery. Researchers tracked 346 patients to see if the device improves survival and quality of life. The goal is to control the disease and reduce symptoms, not to cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSCATHETER AORTIC VALVE IMPLANTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSCATHETER AORTIC VALVE IMPLANTATION

Contacts and locations

Locations

Clinica Mediterranea Neapel

Naples, Italy
Heartcentre Catharina Hospital Eindhoven

Eindhoven, 5623 EJ, Netherlands
Herz- und Gefäßzentrum Bad Bevensen

Bad Bevensen, 29549, Germany
Hospital Alvaro Cunqueiro

Vigo, 36213, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hospital Universitario Virgen de la Victoria

Málaga, 29010, Spain
Hospital Universitario de Salamanca

Salamanca, 37007, Spain
Kath. Marienkrankenhaus

Hamburg, 22087, Germany
MH Hannover

Hanover, 30625, Germany
Morriston Hospital

Swansea, United Kingdom
Ospedale San Raffaele

Milan, 20132, Italy
Oulu University Hospital

Oulu, 90220, Finland
SLK-Kliniken Heilbronn

Heilbronn, 74078, Germany
Schuechtermann-klinik

Bad Rothenfelde, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.